Crescita Therapeutics Inc. (CTX.TO)
CAD 0.57
(1.79%)
CAD 0.57
(1.79%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 10.36 Million CAD | -32.8% |
| 2022 | 13.18 Million CAD | 31.64% |
| 2021 | 10.01 Million CAD | -11.17% |
| 2020 | 11.27 Million CAD | -31.83% |
| 2019 | 16.53 Million CAD | 49.12% |
| 2018 | 11.08 Million CAD | 54.7% |
| 2017 | 7.16 Million CAD | 513.17% |
| 2016 | 1.16 Million CAD | 228.37% |
| 2015 | 356 Thousand CAD | -35.39% |
| 2014 | 551 Thousand CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.93 Million CAD | 10.32% |
| 2024 Q1 | 2.02 Million CAD | -24.43% |
| 2023 Q4 | 2.68 Million CAD | 78.85% |
| 2023 FY | 8.85 Million CAD | -32.8% |
| 2023 Q3 | 1.49 Million CAD | -51.16% |
| 2023 Q2 | 3.06 Million CAD | 12.17% |
| 2023 Q1 | 2.73 Million CAD | -29.58% |
| 2022 Q1 | 2.71 Million CAD | -41.69% |
| 2022 FY | 13.18 Million CAD | 31.64% |
| 2022 Q4 | 3.88 Million CAD | 32.23% |
| 2022 Q3 | 2.93 Million CAD | -19.44% |
| 2022 Q2 | 3.64 Million CAD | 34.48% |
| 2021 FY | 10.01 Million CAD | -11.17% |
| 2021 Q3 | 1.52 Million CAD | -11.44% |
| 2021 Q4 | 4.65 Million CAD | 204.98% |
| 2021 Q1 | 2.11 Million CAD | 33.25% |
| 2021 Q2 | 1.72 Million CAD | -18.62% |
| 2020 Q4 | 1.58 Million CAD | -74.09% |
| 2020 Q2 | 1.09 Million CAD | -55.68% |
| 2020 FY | 11.27 Million CAD | -31.83% |
| 2020 Q1 | 2.46 Million CAD | 15.57% |
| 2020 Q3 | 6.12 Million CAD | 461.26% |
| 2019 Q3 | 3.44 Million CAD | -56.12% |
| 2019 Q4 | 2.13 Million CAD | -38.08% |
| 2019 FY | 16.53 Million CAD | 49.12% |
| 2019 Q1 | 2.92 Million CAD | -32.63% |
| 2019 Q2 | 7.84 Million CAD | 168.0% |
| 2018 Q3 | 3.11 Million CAD | 142.15% |
| 2018 Q4 | 4.34 Million CAD | 39.56% |
| 2018 Q1 | 2.34 Million CAD | 296.45% |
| 2018 FY | 11.08 Million CAD | 54.7% |
| 2018 Q2 | 1.28 Million CAD | -45.11% |
| 2017 Q1 | 1.06 Million CAD | 122.71% |
| 2017 Q4 | 591 Thousand CAD | -61.94% |
| 2017 FY | 7.16 Million CAD | 513.17% |
| 2017 Q3 | 1.55 Million CAD | -60.73% |
| 2017 Q2 | 3.95 Million CAD | 269.97% |
| 2016 Q2 | -18 Thousand CAD | 92.47% |
| 2016 FY | 1.16 Million CAD | 228.37% |
| 2016 Q4 | 480 Thousand CAD | -3.23% |
| 2016 Q1 | -239 Thousand CAD | -150.74% |
| 2016 Q3 | 496 Thousand CAD | 2855.56% |
| 2015 Q4 | 471 Thousand CAD | 202.84% |
| 2015 Q2 | 180 Thousand CAD | 122.22% |
| 2015 Q3 | -458 Thousand CAD | -354.44% |
| 2015 FY | 356 Thousand CAD | -35.39% |
| 2015 Q1 | 81 Thousand CAD | 0.0% |
| 2014 FY | 551 Thousand CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Aurora Cannabis Inc. | 131.46 Million CAD | 92.116% |
| Avicanna Inc. | 6.65 Million CAD | -55.646% |
| Avant Brands Inc. | 12.43 Million CAD | 16.634% |
| Cardiol Therapeutics Inc. | -248.35 Thousand CAD | 4273.059% |
| Knight Therapeutics Inc. | 152.65 Million CAD | 93.211% |
| MediPharm Labs Corp. | 5.85 Million CAD | -77.011% |
| OrganiGram Holdings Inc. | 35.07 Million CAD | 70.45% |
| Canopy Growth Corporation | 80.88 Million CAD | 87.186% |
| Willow Biosciences Inc. | -659 Thousand CAD | 1672.686% |
| Auxly Cannabis Group Inc. | 21.27 Million CAD | 51.29% |